OBJECTIVES: Turkey pharmaceutical market is a growing market in spite of government policies. Public pharmaceutical market rise from 7.9 billion TL to 15.5 billion TL from 2000 to 2009. In addition, Cardiovascular system medicines market rise from 1.3 billion TL to 1.8 billion TL from 2005 to 2010. It was reported that statin market was 21% of the cardiovascular system medicines expenditures. Statins have the same effectiveness and safety profile. So each statin may use instead of others. Internal reference pricing may use for statins in Turkey. The aim of the study is to calculate possible budget impact of jumbo basket application for statins in Turkey. METHODS: Statin consumption for year 2010 was taken from IMS. Possible 4 different budget scenarios were calculated. Scenario A defined as reimburse all statins with the minimum statin price. Scenario B defined as reimburse all stations up to 15% of minimum statin price. Scenario C defined as reimburse all statins up to 10% of average price of statins. Scenario D defined as reimburse all statins as the calculation = (average price + minimum price)/2. RESULTS: Statin expenditure was 496 million TL in 2010. If Scenario A or B may be used, the new statin expenditure may be 85 million or 97 million TL, respectively. If Scenario C or D may be used, the new statin expenditure may be 320 million TL or 308 million TL, respectively.  CONCLUSIONS: However, Scenario A or B may offer maximum decrease in statin budget, industry may not run business under the situation. Scenario C or D may be acceptable for the industry and offer government 37% or 35% extra decrease in statin expenditure. This pilot study may spotlight possible opportunities in the controlling statin market budget for government.